Company Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
22.34 ^USD	+2.81%		+13.75%	-0.76%

03-25	Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	MT
03-25	Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	CI

Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

Number of employees: 29

Managers	Title	Age	Since
Remi Barbier CEO	Chief Executive Officer	64	30/04/98
Eric Schoen DFI	Director of Finance/CFO	55	30/09/18
James Kupiec CTO	Chief Tech/Sci/R&D Officer	-	03/01/21
Michael Zamloot CTO	Chief Tech/Sci/R&D Officer	-	-
George B. Thornton CTO	Chief Tech/Sci/R&D Officer	-	-
Michael O'Donnell BRD	Director/Board Member	65	31/05/98
Robert Cook LAW	General Counsel	60	30/09/22
Michael Marsman LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Remi Barbier CEO	Chief Executive Officer	64	30/04/98
Robert Gussin BRD	Director/Board Member	86	28/02/03
Patrick Scannon BRD	Director/Board Member	76	06/12/07
Sanford Robertson BRD	Director/Board Member	92	31/08/98
Richard Barry BRD	Director/Board Member	65	10/06/21
Michael O'Donnell BRD	Director/Board Member	65	31/05/98
Claude Nicaise BRD	Director/Board Member	71	12-06
Robert Anderson BRD	Director/Board Member	58	12-06
Pierre Gravier BRD	Director/Board Member	39	12-06

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	43,245,758	40,141,808 ( 92.82 %)	0	92.82 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 6.623 %	2,862,690	6.623 %	58 M $
Vanguard Fiduciary Trust Co. 5.378 %	2,324,626	5.378 %	47 M $
Remi Barbier 3.096 %	1,338,157	3.096 %	27 M $
Sanford Robertson 2.962 %	1,280,221	2.962 %	26 M $
STATE STREET CORPORATION 2.475 %	1,069,649	2.475 %	22 M $
Geode Capital Management LLC 2.022 %	873,996	2.022 %	18 M $
Gallacher Capital Management LLC 1.346 %	581,606	1.346 %	12 M $
Morgan Stanley Investment Management, Inc. 1.252 %	541,273	1.252 %	11 M $
Cowen & Co. LLC 1.157 %	500,000	1.157 %	10 M $
Richard Barry 1.086 %	469,562	1.086 %	10 M $

Name	Equities	%	Valuation
Raymond James & Associates, Inc. -	28,885	-	116 407 $
Zürcher Kantonalbank (Investment Management) -	2,257	-	9 096 $
Cutler Group LLC -	1,120	-	4 514 $
Salem Investment Counselors, Inc. -	110	-	443 $
PFS Partners LLC -	80	-	322 $

Cassava Sciences, Inc.

6801 North Capital of Texas Highway Suite 300

78731, Austin

+512 501 2444

http://www.cassavasciences.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

22.34 USD

Average target price

124 USD

Spread / Average Target

+455.06%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CASSAVA SCIENCES, INC.	-0.76%	966M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs